CR20150297A - Producto de comicronización que comprende acetato de ulipristal - Google Patents

Producto de comicronización que comprende acetato de ulipristal

Info

Publication number
CR20150297A
CR20150297A CR20150297A CR20150297A CR20150297A CR 20150297 A CR20150297 A CR 20150297A CR 20150297 A CR20150297 A CR 20150297A CR 20150297 A CR20150297 A CR 20150297A CR 20150297 A CR20150297 A CR 20150297A
Authority
CR
Costa Rica
Prior art keywords
ulipristal acetate
comicronization
product
comicronization product
ulipristal
Prior art date
Application number
CR20150297A
Other languages
English (en)
Inventor
Florian Battung
Pierre-Yves Juvin
Jérôme Hecq
Aude Colin
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of CR20150297A publication Critical patent/CR20150297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

La presente invención tiene por objeto un producto de comicronización que comprende una sustancia activa elegida entre el grupo constituido por el acetato de ulipristal, un metabolito del acetato de ulipristal y sus mezclas, y un tensioactivo sólido aceptable desde el punto de vista farmacéutico. La invención se refiere también a una composición farmacéutica que comprende dicho producto de comicronización y sus utilizaciones terapéuticas.
CR20150297A 2012-11-08 2015-06-05 Producto de comicronización que comprende acetato de ulipristal CR20150297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1260603A FR2997627B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant de l'ulipristal acetate
PCT/FR2013/052670 WO2014072646A1 (fr) 2012-11-08 2013-11-07 Produit de co-micronisation comprenant de l'ulipristal acetate

Publications (1)

Publication Number Publication Date
CR20150297A true CR20150297A (es) 2015-08-14

Family

ID=47878175

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150297A CR20150297A (es) 2012-11-08 2015-06-05 Producto de comicronización que comprende acetato de ulipristal

Country Status (30)

Country Link
US (2) US9610293B2 (es)
EP (1) EP2916871B1 (es)
JP (1) JP2015536968A (es)
KR (1) KR20150093170A (es)
CN (1) CN104902928B (es)
AR (1) AR093402A1 (es)
AU (1) AU2013343320B2 (es)
BR (1) BR112015010271B1 (es)
CA (1) CA2890272A1 (es)
CR (1) CR20150297A (es)
CY (1) CY1119542T1 (es)
DK (1) DK2916871T3 (es)
EA (1) EA027641B1 (es)
EC (1) ECSP15022442A (es)
ES (1) ES2606307T3 (es)
FR (1) FR2997627B1 (es)
GE (1) GEP201706637B (es)
HR (1) HRP20161624T1 (es)
HU (1) HUE031911T2 (es)
LT (1) LT2916871T (es)
MD (1) MD4563C1 (es)
MX (1) MX363699B (es)
PL (1) PL2916871T3 (es)
PT (1) PT2916871T (es)
RS (1) RS55429B1 (es)
SI (1) SI2916871T1 (es)
SM (1) SMT201600445B (es)
TW (1) TWI617325B (es)
UA (1) UA117465C2 (es)
WO (1) WO2014072646A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
CN103923154B (zh) * 2013-01-16 2017-09-26 杭州容立医药科技有限公司 醋酸乌利司他的共晶及制备方法
CN105663140A (zh) * 2014-11-21 2016-06-15 四川海思科制药有限公司 一种含醋酸乌利司他的药物组合物及其制备方法
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
CN105919150A (zh) * 2016-05-12 2016-09-07 高洁珺 一种代替压片工艺中化工添加剂的方法
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
ATE497745T1 (de) 2004-07-09 2011-02-15 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
WO2008037044A1 (en) 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
US7867515B2 (en) 2006-12-20 2011-01-11 TEVA Woman's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
AU2007339820A1 (en) * 2006-12-28 2008-07-10 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
US9616073B2 (en) 2009-04-14 2017-04-11 Laboratoire Hra-Pharma Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate

Also Published As

Publication number Publication date
AU2013343320A1 (en) 2015-06-04
EA201500513A1 (ru) 2015-08-31
CN104902928A (zh) 2015-09-09
AU2013343320B2 (en) 2018-03-08
DK2916871T3 (da) 2017-01-02
TW201427718A (zh) 2014-07-16
SMT201600445B (it) 2017-01-10
LT2916871T (lt) 2016-12-27
UA117465C2 (uk) 2018-08-10
CA2890272A1 (fr) 2014-05-15
RS55429B1 (sr) 2017-04-28
FR2997627A1 (fr) 2014-05-09
EA027641B1 (ru) 2017-08-31
HRP20161624T1 (hr) 2017-01-27
JP2015536968A (ja) 2015-12-24
PL2916871T3 (pl) 2017-02-28
BR112015010271B1 (pt) 2020-04-22
US9610293B2 (en) 2017-04-04
WO2014072646A1 (fr) 2014-05-15
MD4563B1 (ro) 2018-05-31
KR20150093170A (ko) 2015-08-17
SI2916871T1 (sl) 2017-03-31
MX2015005762A (es) 2016-02-11
PT2916871T (pt) 2016-12-15
EP2916871B1 (fr) 2016-09-14
MX363699B (es) 2019-03-28
TWI617325B (zh) 2018-03-11
CY1119542T1 (el) 2018-03-07
FR2997627B1 (fr) 2015-01-16
EP2916871A1 (fr) 2015-09-16
ECSP15022442A (es) 2016-01-29
BR112015010271A8 (pt) 2019-10-01
AR093402A1 (es) 2015-06-03
MD4563C1 (ro) 2018-12-31
BR112015010271A2 (pt) 2017-07-11
ES2606307T3 (es) 2017-03-23
CN104902928B (zh) 2018-10-23
US20170157146A1 (en) 2017-06-08
HUE031911T2 (en) 2017-08-28
MD20150053A2 (ro) 2015-10-31
US20150290218A1 (en) 2015-10-15
GEP201706637B (en) 2017-03-10

Similar Documents

Publication Publication Date Title
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
PE20140255A1 (es) Tableta dispersable en forma oral
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
IN2014MN02236A (es)
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
CL2015000290A1 (es) Compuestos derivados de ariletinilo. moduladores alostéricos del receptor de glutamato mglur5; proceso de obtencion; composicion farmaceuticas: y su uso en el tratamiento o prevencon de la esquizofenia, enfermedades cognitivas, sindrome de x fragil o autismo
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
BR112015021769A2 (pt) composições farmacêuticas compreendendo um agente ativo
IN2014DN07897A (es)
EA201400808A1 (ru) Стабилизированные фармацевтические составы сильнодействующего ингибитора вируса гепатита с
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
CL2018001236A1 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.